Naldemedine was found to be safe and effective for increasing bowel movement frequency and improving quality of life in patients with chronic non-cancer pain and opioid-induced constipation.
In patients with opioid-induced constipation, naldemedine was shown to improve patient assessment of symptoms and quality of life.
Naldemedine, a recently approved agent for opioid-induced constipation, showed good safety and significantly higher responder rates than placebo in a couple of 12-week, international, randomized trials.
Clinical Pain Advisor Articles
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- Predicting Pain Chronicization After Spine Surgery
- Chronic Low Back Pain Levels Vary Between Sex and Race
- FDA Approval of Medication With a Digital Monitoring System: Major Breakthrough or "Brave New World"?
- Errors in Clinical Notes Generated by Speech Recognition Are Not Uncommon
- Effectiveness of Medication for Opioid Use Disorder on Mortality After Overdose Reviewed Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?